Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$9.10
0.040.44%
Pre-Market: Apr 4, 7:45 PM EDT
Comments
Loading...
Capricor Therapeutics Analyst Ratings and Price Targets | NASDAQ:CAPR | Benzinga
Capricor Therapeutics Inc has a consensus price target of $39.29 based on the ratings of 7 analysts. The high is $77 issued by HC Wainwright & Co. on March 20, 2025. The low is $25 issued by Maxim Group on September 25, 2024. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, HC Wainwright & Co., and HC Wainwright & Co. on March 20, 2025, March 20, 2025, and March 17, 2025, respectively. With an average price target of $61.33 between Cantor Fitzgerald, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 573.99% upside for Capricor Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
HC Wainwright & Co.
Jones Trading
Piper Sandler
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Capricor Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/20/2025 | Buy Now | 229.67% | Cantor Fitzgerald | Kristen Kluska66% | $30 → $30 | Reiterates | Overweight → Overweight | Get Alert |
| 03/20/2025 | Buy Now | 746.15% | HC Wainwright & Co. | Joseph Pantginis44% | $77 → $77 | Reiterates | Buy → Buy | Get Alert |
| 03/17/2025 | Buy Now | 746.15% | HC Wainwright & Co. | Joseph Pantginis44% | $77 → $77 | Reiterates | Buy → Buy | Get Alert |
| 03/04/2025 | Buy Now | 746.15% | HC Wainwright & Co. | Joseph Pantginis44% | $77 → $77 | Reiterates | Buy → Buy | Get Alert |
| 01/02/2025 | Buy Now | 746.15% | HC Wainwright & Co. | Joseph Pantginis44% | $77 → $77 | Reiterates | Buy → Buy | Get Alert |
| 11/18/2024 | Buy Now | 339.56% | Jones Trading | Catherine Novack25% | → $40 | Initiates | → Buy | Get Alert |
| 11/14/2024 | Buy Now | 746.15% | HC Wainwright & Co. | Joseph Pantginis44% | $77 → $77 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2024 | Buy Now | 229.67% | Cantor Fitzgerald | Kristen Kluska66% | $25 → $30 | Maintains | Overweight | Get Alert |
| 10/21/2024 | Buy Now | 284.62% | Piper Sandler | Edward Tenthoff51% | → $35 | Initiates | → Overweight | Get Alert |
| 10/11/2024 | Buy Now | 746.15% | HC Wainwright & Co. | Joseph Pantginis44% | $40 → $77 | Maintains | Buy | Get Alert |
| 10/09/2024 | Buy Now | 339.56% | HC Wainwright & Co. | Joseph Pantginis44% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 09/25/2024 | Buy Now | 372.53% | Oppenheimer | Leland Gershell67% | $15 → $43 | Maintains | Outperform | Get Alert |
| 09/25/2024 | Buy Now | 174.73% | Maxim Group | Jason McCarthy41% | $12 → $25 | Maintains | Buy | Get Alert |
| 09/24/2024 | Buy Now | 339.56% | HC Wainwright & Co. | Joseph Pantginis44% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 09/23/2024 | Buy Now | 64.84% | Oppenheimer | Leland Gershell67% | $15 → $15 | Reiterates | Outperform → Outperform | Get Alert |
| 09/20/2024 | Buy Now | -12.09% | Cantor Fitzgerald | Kristen Kluska66% | $8 → $8 | Reiterates | Overweight → Overweight | Get Alert |
| 09/17/2024 | Buy Now | 64.84% | Oppenheimer | Leland Gershell67% | $14 → $15 | Maintains | Outperform | Get Alert |
| 09/17/2024 | Buy Now | 31.87% | Maxim Group | Jason McCarthy41% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 09/17/2024 | Buy Now | 339.56% | HC Wainwright & Co. | Joseph Pantginis44% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 07/02/2024 | Buy Now | 339.56% | HC Wainwright & Co. | Joseph Pantginis44% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 05/17/2024 | Buy Now | 53.85% | Oppenheimer | Leland Gershell67% | → $14 | Initiates | → Outperform | Get Alert |
| 05/14/2024 | Buy Now | 339.56% | HC Wainwright & Co. | Joseph Pantginis44% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | -12.09% | Cantor Fitzgerald | Kristen Kluska66% | $8 → $8 | Reiterates | Overweight → Overweight | Get Alert |
| 05/14/2024 | Buy Now | 174.73% | Ladenburg Thalmann | Aydin Huseynov35% | $24 → $25 | Maintains | Buy | Get Alert |
| 04/25/2024 | Buy Now | 339.56% | HC Wainwright & Co. | Joseph Pantginis44% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 339.56% | HC Wainwright & Co. | Joseph Pantginis44% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 01/05/2024 | Buy Now | -12.09% | Cantor Fitzgerald | Kristen Kluska66% | → $8 | Initiates | → Overweight | Get Alert |
| 10/04/2023 | Buy Now | 339.56% | HC Wainwright & Co. | Joseph Pantginis44% | $18 → $40 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 97.8% | HC Wainwright & Co. | Joseph Pantginis44% | → $18 | Reiterates | Buy → Buy | Get Alert |
| 03/16/2023 | Buy Now | 97.8% | HC Wainwright & Co. | Joseph Pantginis44% | → $18 | Reiterates | → Buy | Get Alert |
| 10/26/2022 | Buy Now | 64.84% | Ladenburg Thalmann | Aydin Huseynov35% | → $15 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Capricor Therapeutics (CAPR) stock?
The latest price target for Capricor Therapeutics (NASDAQ:CAPR) was reported by Cantor Fitzgerald on March 20, 2025. The analyst firm set a price target for $30.00 expecting CAPR to rise to within 12 months (a possible 229.67% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Capricor Therapeutics (CAPR)?
The latest analyst rating for Capricor Therapeutics (NASDAQ:CAPR) was provided by Cantor Fitzgerald, and Capricor Therapeutics reiterated their overweight rating.
When was the last upgrade for Capricor Therapeutics (CAPR)?
There is no last upgrade for Capricor Therapeutics
When was the last downgrade for Capricor Therapeutics (CAPR)?
There is no last downgrade for Capricor Therapeutics.
When is the next analyst rating going to be posted or updated for Capricor Therapeutics (CAPR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Capricor Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Capricor Therapeutics was filed on March 20, 2025 so you should expect the next rating to be made available sometime around March 20, 2026.
Is the Analyst Rating Capricor Therapeutics (CAPR) correct?
While ratings are subjective and will change, the latest Capricor Therapeutics (CAPR) rating was a reiterated with a price target of $30.00 to $30.00. The current price Capricor Therapeutics (CAPR) is trading at is $9.10, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.